? The broad, long-term objective of the current research is to improve treatment for alcohol and other drug (AOD) use disorders through development of an innovative alternative approach to preventing AOD relapse.
The specific aims of the research are 1) To develop a manual and therapist adherence/competence measures to standardize delivery of a Mindfulness-Based Relapse Prevention (MBRP) program for post-treatment relapse prevention of AOD problems, which will be patterned after Mindfulness-Based Cognitive Therapy for Depression (Segal, Teasdale & Williams, 2002) and incorporate cognitive-behavioral relapse prevention strategies (Daley & Marlatt, 1997); 2) To conduct a pilot randomized clinical trial to assess the feasibility of recruiting and retaining individuals for a large scale study and to determine effect size of MBRP in comparison to cognitive-behavioral group relapse prevention based on Marlatt's Relapse Prevention model (RP) alone (Daley & Marlatt, 1997). Both MBRP and RP conditions will be compared to a treatment as usual control group (TAU) in a sample of participants enrolled in continuing care following Intensive Outpatient Treatment, at baseline, post-treatment, 2-, and 4-months following the baseline assessment; and 3) Evaluate potential mediators of MBRP and RP treatment efficacy. We hypothesize that both MBRP and RP will be more efficacious than TAU. We hypothesize MBRP efficacy will be mediated by meta-cognitive processes, thought suppression, locus of control, skills to cope with urges and cravings, negative affect and meditation practice. We hypothesize RP efficacy will be mediated by self-efficacy, negative affect and coping abilities. This research builds on over 25 years of developing and implementing RP interventions. MBRP incorporates specific alcohol and drug-focused cognitive therapy techniques with an additional emphasis on mindfulness skills, and builds upon the Investigator's prior work on meditation-based interventions. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21DA019562-02
Application #
7268048
Study Section
Human Development Research Subcommittee (NIDA)
Program Officer
Onken, Lisa
Project Start
2006-06-15
Project End
2009-02-28
Budget Start
2007-06-01
Budget End
2009-02-28
Support Year
2
Fiscal Year
2007
Total Cost
$184,020
Indirect Cost
Name
University of Washington
Department
Psychology
Type
Schools of Arts and Sciences
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Grow, Joel C; Collins, Susan E; Harrop, Erin N et al. (2015) Enactment of home practice following mindfulness-based relapse prevention and its association with substance-use outcomes. Addict Behav 40:16-20
Bowen, Sarah; Witkiewitz, Katie; Clifasefi, Seema L et al. (2014) Relative efficacy of mindfulness-based relapse prevention, standard relapse prevention, and treatment as usual for substance use disorders: a randomized clinical trial. JAMA Psychiatry 71:547-56
Hsu, Sharon Hsin; Collins, Susan E; Marlatt, G Alan (2013) Examining psychometric properties of distress tolerance and its moderation of mindfulness-based relapse prevention effects on alcohol and other drug use outcomes. Addict Behav 38:1852-8
Witkiewitz, Katie; Bowen, Sarah; Douglas, Haley et al. (2013) Mindfulness-based relapse prevention for substance craving. Addict Behav 38:1563-71
Bowen, Sarah; Kurz, Andrew S (2012) Between-session practice and therapeutic alliance as predictors of mindfulness after mindfulness-based relapse prevention. J Clin Psychol 68:236-45
Witkiewitz, Katie; Bowen, Sarah (2010) Depression, craving, and substance use following a randomized trial of mindfulness-based relapse prevention. J Consult Clin Psychol 78:362-74
Chawla, Neharika; Collin, Susan; Bowen, Sarah et al. (2010) The mindfulness-based relapse prevention adherence and competence scale: development, interrater reliability, and validity. Psychother Res 20:388-97
Bowen, Sarah; Chawla, Neharika; Collins, Susan E et al. (2009) Mindfulness-based relapse prevention for substance use disorders: a pilot efficacy trial. Subst Abus 30:295-305